Behavioral Health Business August 26, 2024
Morgan Gonzales

Ketamine therapy provider HOPE Therapeutics announced it plans to acquire five ketamine clinics and reach $100 million in annual revenue in less than a year.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), announced on Monday that it has secured $30 million in debt to finance the acquisitions. The company is apparently targeting five unspecified clinics in the Western U.S.

“We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care and demonstrate best practices for mental health professionals around the world,” the company’s leadership said in a statement.

Jonathan Javitt and Matthew Duffy are co-CEOs of HOPE Therapeutics.

HOPE Therapeutics also plans to expand...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mental Health, Mergers & Acquisitions / JV, Provider, Trends
Iris Telehealth Acquires innovaTel to Expand Telepsychiatry Services
Ascension hospital opens intensive mental health therapy for patients 55 and older
In a showdown of psychotherapists vs. ChatGPT, the latter wins, new study finds
Mental health is overwhelming pediatricians — how 1 provider helps
Apple Launches Mental Health Study Using iPhone, Watch and AirPods Data

Share This Article